Strategies and challenges to myocardial replacement therapy

Stem Cells Translational Medicine

Volumn 5, Issue 4, 2016, Pages 410-416

  Feric, Nicole T ^a   Radisic, Milica ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; BONE MORPHOGENETIC PROTEIN 4; MICRORNA; STROMAL CELL DERIVED FACTOR 1; THYMOSIN BETA4; VASCULOTROPIN;

ADULT STEM CELL; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIAC STEM CELL; CELL SUSPENSION; CELL THERAPY; DNA MODIFICATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART INJURY; HEART MUSCLE BIOPSY; HUMAN; IN VITRO STUDY; META ANALYSIS (TOPIC); MYOCARDIAL REPLACEMENT THERAPY; NONHUMAN; PERICARDIAL PATCH; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TISSUE ENGINEERING; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CYTOLOGY; HEART DISEASES; HEART TRANSPLANTATION; PATHOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; TISSUE ENGINEERING;

EID: 84961282358     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0288     Document Type: Article

References (93)

1. Mendis S, Davis S, Norrving B. Organizational update: The World Health Organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 2015;46:e121-e122.
2. Reinecke H, Minami E, Zhu WZ et al. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res 2008;103:1058-1071.
3. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
4. Porrello ER, Mahmoud AI, Simpson E et al. Transient regenerative potential of the neonatal mouse heart. Science 2011;331:1078-1080.
5. Tous E, Purcell B, Ifkovits JL et al. Injectable acellular hydrogels for cardiac repair. J Cardiovasc Transl Res 2011;4:528-542.
6. Chong JJ, Yang X, Don CW et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts.Nature 2014;510:273-277.
7. Jawad H, Ali NN, Lyon AR et al. Myocardial tissue engineering: A review. J Tissue Eng Regen Med 2007;1:327-342.
8. Eulalio A, Mano M, Dal Ferro M et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012;492:376-381.
9. Sirish P, López JE, Li N et al. MicroRNA profiling predicts a variance in the proliferative potential of cardiac progenitor cells derived from neonatal and adult murine hearts. J Mol Cell Cardiol 2012;52:264-272.
10. Porrello ER, Johnson BA, Aurora AB et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res 2011;109:670-679.
11. Hullinger TG, Montgomery RL, Seto AG et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012;110: 71-81.
12. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012; 11:860-872.
13. Davis DR, Zhang Y, Smith RR et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One 2009;4:e7195.
14. Chimenti I, Smith RR, Li TS et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 2010;106:971-980.
15. Malliaras K, Makkar RR, Smith RR et al. Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 2014;63:110-122.
16. Ebert AD, Diecke S, Chen IY et al. Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: Where do we stand? EMBO Mol Med 2015;7:1090-1103.
17. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
18. Yang L, Soonpaa MH, Adler ED et al. Human cardiovascular progenitor cells develop from a KDR1embryonic-stem-cell-derived population. Nature 2008;453:524-528.
19. Zhang J, Wilson GF, Soerens AG et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104:e30-e41.
20. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
21. Nichols J, Smith A. Naive and primed pluripotent states. Cell Stem Cell 2009;4:487-492.
22. Gafni O, Weinberger L, Mansour AA et al. Derivation of novel human ground state naive pluripotent stem cells. Nature 2013;504:282-286.
23. Honda A, Hatori M, Hirose M et al. Naivelike conversion overcomes the limited differentiation capacity of induced pluripotent stem cells. J Biol Chem 2013;288:26157-26166.
24. Rais Y, Zviran A, Geula S et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 2013;502:65-70.
25. Kehat I, Kenyagin-Karsenti D, Snir M et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001;108:407-414.
26. Mummery C, van der Heyden MA, de Boer TP et al. Cardiomyocytes from human and mouse embryonic stem cells. Methods Mol Med 2007;140:249-272.
27. Burridge PW, Thompson S, Millrod MA et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011;6:e18293.
28. Kattman SJ, Witty AD, Gagliardi M et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation ofmouse and human pluripotent stemcell lines. Cell Stem Cell 2011;8:228-240.
29. Paige SL, Osugi T, Afanasiev OK et al. Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One 2010;5:e11134.
30. Zhang J, Klos M, Wilson GF et al. Extracellular matrix promotes highly efficient cardiac differentiation of humanpluripotent stem cells: the matrix sandwich method. Circ Res 2012; 111:1125-1136.
31. Lian X, Zhang J, Azarin SM et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/b-catenin signaling under fully defined conditions. Nat Protoc 2013;8:162-175.
32. Synnergren J, Améen C, Jansson A et al. Global transcriptional profiling reveals similarities and differences between human stem cellderived cardiomyocyte clusters and heart tissue. Physiol Genomics 2012;44:245-258.
33. Mummery C, Ward-van Oostwaard D, Doevendans P et al. Differentiation of human embryonic stem cells to cardiomyocytes: Role of coculture with visceral endoderm-like cells. Circulation 2003;107:2733-2740.
34. Robertson C, Tran DD, George SC. Concise review: Maturation phases of human pluripotent stem cell-derived cardiomyocytes. STEM CELLS 2013;31:829-837.
35. Mummery CL, Zhang J, Ng E S et al.Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: Amethods overview. Circ Res 2012;111:344-358.
36. O’Hara T, Virág L, Varró A et al. Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation. PLOS Comput Biol 2011;7: e1002061.
37. Pillekamp F, Haustein M, Khalil M et al. Contractile properties of early human embryonic stem cell-derived cardiomyocytes: Beta-adrenergic stimulation induces positive chronotropy and lusitropy but not inotropy. Stem Cells Dev 2012;21:2111-2121.
38. Schaaf S, Shibamiya A, Mewe M et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 2011;6:e26397.
39. Poon E, Kong CW, Li RA. Human pluripotent stem cell-based approaches for myocardial repair: From the electrophysiological perspective. Mol Pharm 2011;8:1495-1504.
40. Itzhaki I, Schiller J, Beyar R et al. Calcium handling in embryonic stem cell-derived cardiac myocytes: Of mice and men. Ann N Y Acad Sci 2006;1080:207-215.
41. Lee AS, Tang C, Rao MS et al. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 2013;19:998-1004.
42. Ieda M, Fu JD, Delgado-Olguin P et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010;142:375-386.
43. Efe JA, Hilcove S, Kim J et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011;13:215-222.
44. Qian L, Huang Y, Spencer CI et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012; 485:593-598.
45. Islas JF, Liu Y, Weng KC et al. Transcription factors ETS2 and MESP1 transdifferentiate human dermal fibroblasts into cardiac progenitors. Proc Natl Acad Sci USA 2012;109: 13016-13021.
46. Fu JD, Stone NR, Liu L et al. Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Rep 2013;1:235-247.
47. Nam YJ, Lubczyk C, Bhakta M et al. Induction of diverse cardiac cell types by reprogramming fibroblasts with cardiac transcription factors. Development 2014;141:4267-4278.
48. Wada R, Muraoka N, Inagawa K et al. Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. Proc Natl Acad Sci USA 2013;110:12667-12672.
49. Sanganalmath SK, Bolli R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013; 113:810-834.
50. Gnecchi M, He H, Liang OD et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-368.
51. Zangi L, Lui KO, von Gise A et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 2013;31: 898-907.
52. Smart N, Bollini S, Dubé KN et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 2011;474: 640-644.
53. Chung ES, Miller L, Patel AN et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 nonviral gene therapy in chronic ischaemic heart failure patients: The STOP-HF randomized Phase II trial. Eur Heart J 2015;36:2228-2238.
54. Korf-Klingebiel M, Reboll MR, Klede S et al. Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nat Med 2015;21:140-149.
55. Lipinski MJ, Biondi-Zoccai GG, Abbate A et al. Impact of intracoronary cell therapyon left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007;50:1761-1767.
56. Menasché P, Vanneaux V, Hagége A et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: First clinical case report. Eur Heart J 2015;36: 2011-2017.
57. Prowse AB, Timmins NE, Yau TM et al. Transforming the promise of pluripotent stem cell-derived cardiomyocytes to a therapy: challenges and solutions for clinical trials. Can J Cardiol 2014;30:1335-1349.
58. Ye L, Chang YH, Xiong Q et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells [published correction appears in Cell Stem Cell 2015. Jan 8;16: 102]. Cell Stem Cell 2014;15:750-761.
59. Laflamme MA, Chen KY, Naumova AV et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25:1015-1024.
60. van Laake LW, Passier R, Doevendans PA et al. Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ Res 2008;102:1008-1010.
61. Gepstein L, Ding C, Rahmutula D et al. In vivo assessment of the electrophysiological integration and arrhythmogenic risk ofmyocardial cell transplantation strategies [published correction appears in STEM CELLS 2011. Sep;29(9):1475]. STEM CELLS 2010;28:2151-2161.
62. Shiba Y, Fernandes S, Zhu WZ et al. HumanES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 2012;489:322-325.
63. Nunes SS, Miklas JW, Liu J et al. Biowire:A platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods 2013;10:781-787.
64. Kehat I, Khimovich L, Caspi O et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004;22:1282-1289.
65. Schram G, Pourrier M, Melnyk P et al. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res 2002;90:939-950.
66. Yang X, Pabon L, Murry CE. Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res 2014;114:511-523.
67. Feric NT, RadisicM. Maturinghumanpluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Adv Drug Deliv Rev 2016;96:110-134.
68. Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: State of the art. Circ Res 2014;114:354-367.
69. Sun X, Nunes SS. Overview of hydrogelbased strategies for application in cardiac tissue regeneration. Biomed Mater 2015;10:034005.
70. Reis LA, Chiu LL, FericNet al. Biomaterials in myocardial tissue engineering. J Tissue Eng Regen Med 2016;10:11-28.
71. Zhang B, Xiao Y, Hsieh A, Thavandiran N, Radisic M. Micro-and nanotechnology in cardiovascular tissue engineering. Nanotechnology 2011;22:494003.
72. Park H, Larson BL, Guillemette MD et al. The significance of pore microarchitecture in a multi-layered elastomeric scaffold for contractile cardiac muscle constructs. Biomaterials 2011;32:1856-1864.
73. Nawroth JC, Lee H, Feinberg AW et al. A tissue-engineered jellyfish with biomimetic propulsion. Nat Biotechnol 2012;30:792-797.
74. Liau B, Christoforou N, Leong KW et al. Pluripotent stem cell-derived cardiac tissue patch with advanced structure and function. Biomaterials 2011;32:9180-9187.
75. Tulloch NL, Muskheli V, Razumova MV et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 2011;109:47-59.
76. Zimmermann WH, Melnychenko I, Wasmeier G et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 2006;12:452-458.
77. Naito H, Melnychenko I, Didié M et al. Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 2006;114(suppl):I72-I78.
78. Sekine H, Shimizu T, Hobo K et al. Endothelial cell coculture within tissue-engineered cardiomyocyte sheets enhances neovascularization and improves cardiac function of ischemic hearts. Circulation 2008;118(suppl): S145-S152.
79. Riegler J, Gillich A, Shen Q et al. Cardiac tissue slice transplantation as a model to assess tissue-engineered graft thickness, survival, and function. Circulation 2014;130 (suppl 1):S77-S86.
80. Sun X, Altalhi W, Nunes SS. Vascularization strategies of engineered tissues and their application in cardiac regeneration. Adv Drug Deliv Rev 2016;96:183-194.
81. Mohanty S, Larsen LB, Trifol J et al. Fabrication of scalable and structured tissue engineering scaffolds using water dissolvable sacrificial 3D printed moulds. Mater Sci Eng C 2015;55:569-578.
82. Zhao X, Liu L, Wang J et al. In vitro vascularization of a combined system based on a 3D printing technique. J Tissue Eng Regen Med 2014;(in press).
83. Masuda S, Shimizu T. Three-dimensional cardiac tissue fabrication based on cell sheet technology. Adv Drug Deliv Rev 2016;96:103-109.
84. Zhang B, Montgomery M, Davenport-Huyer L et al. Platform technology for scalable assembly of instantaneously functional mosaic tissues. Sci Adv 2015;1:e1500423.
85. Gerbin KA, Yang X, Murry CE et al. Enhanced electrical integration of engineered human myocardium via intramyocardial versus epicardial delivery in infarcted rat hearts. PLoS One 2015;10:e0131446.
86. Mandarim-de-Lacerda CA, Meirelles Pereira LM. Numerical density of cardiomyocytes in chronic nitric oxide synthesis inhibition. Pathobiology 2000;68:36-42.
87. Wei K, Serpooshan V, Hurtado C et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 2015; 525:479-485.
88. Smart N, Bollini S, Dubé KN et al. Myocardial regeneration: Expanding the repertoire of thymosinb4 in the ischemic heart. AnnNY Acad Sci 2012;1269:92-101.
89. Bett GC, Kaplan AD, Lis A et al. Electronic “expression” of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells. Heart Rhythm 2013;10:1903-1910.
90. Fu JD, Rushing SN, Lieu DK et al. Distinct roles of microRNA-1 and-499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One 2011;6:e27417.
91. Lieu DK, Fu JD, Chiamvimonvat N et al. Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Arrhythm Electrophysiol 2013;6: 191-201.
92. Lin C-J, Lin C-Y, Chen C-H et al. Partitioning the heart: Mechanisms of cardiac septation and valve development. Development 2012; 139:3277-3299.
93. Arnal-Pastor M, Chachques J-C, Monleón Pradas M et al. Biomaterials for cardiac tissue engineering. In: Andrades JA, ed. Regenerative Medicine and Tissue Engineering, Rijeka, Croatia: InTech, 2013.